In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Brenda Sandburg

New York, NY
Brenda Sandburg is a senior writer who covers legal issues and FDA regulatory policy, with a particular focus on patents, biosimilars, and government investigations. She spent 10 years writing for legal publications between stints at The Pink Sheet and blends these experiences to provide in-depth analysis of events. An aspiring photographer, she enjoys taking photos to accompany news stories.

Latest From Brenda Sandburg

RSV Vaccine May Be On Market In 2023, CDC’s ACIP Anticipates

Panel expects to review five respiratory syncytial virus vaccines and vote on one or two of them in June 2023 and others four months later. Sanofi presents results of three clinical trials of its monoclonal antibody nirsevimab, which is on track to be the second RSV prophylaxis for infants.

Advisory Committees Vaccines

Three Influenza Vaccines Are Optimal For Adults 65 And Older, CDC Panel Votes

Higher dose or adjuvanted seasonal flu vaccines – Fluzone, Fluad and Flubok – provide benefit over other vaccines for older adults, advisory committee concludes. Merck’s PCV15 pneumococcal vaccine and GSK’s Priorix MMR vaccine are recommended for pediatric use by ACIP.

Advisory Committees Vaccines

COVID-19 Vaccine Dosing Interval Studies Advocated By US FDA, ACIP

FDA’s Doran Fink and CDC’s ACIP members say vaccine manufacturers could conduct a study to determine whether longer intervals between doses would provide greater effectiveness and longer durability. Right now, they are relying on international data.

Coronavirus COVID-19 Vaccines

COVID-19 Vaccines In Children Under Five Get CDC Backing As Panel Worries FDA Didn’t Go Far Enough

Calling Moderna’s and Pfizer’s vaccines ‘options’ for young children downplays the risks to the population, some CDC advisory committee members argue as they urge a strong message for vaccination given the more than 200 COVID-19 deaths in children six months to five years.

Coronavirus COVID-19 Vaccines

US FDA’s Califf Acknowledges There Is ‘Price To Pay’ For Missed Inspections

Commissioner Califf is questioned about the backlog of inspections and fact FDA staff are continuing to work remotely at Senate HELP Committee hearing. Senator Burr promises to be a roadblock to emergency COVID-19 funding.

Manufacturing Coronavirus COVID-19

US FDA’s Califf Notes ‘Price To Pay’ For Missed Inspections During Senate COVID Funding Hearing

As Senate HELP Committee meetings questioned Commissioner Califf about backlog of inspections and FDA staff continuing to work remotely, Sen. Burr promises to be a roadblock to emergency COVID-19 funding.

Manufacturing Coronavirus COVID-19
See All